#FUJICORPORATION

For the third quarter of fiscal year ending March 2026, net sales were JPY 127,291 million (36.0% YoY increase), operating income was JPY 18,847 million (92.5% YoY increase), and net income attributable to owners of parent was JPY 16,072 million (90.2% YoY increase).

Revised full-year sales for the fiscal year ending March 2026 to JPY 183.0 billion (up 10.9% from previous forecast), operating income to JPY 30.6 billion (up 39.1%), and net income attributable to owners of parent to JPY 24.4 billion (up 38.6%)

For the third quarter of the fiscal year ending March 2026, net sales amounted to 127.291 billion yen (36.0% Year-over-Year increase), operating income was 18.847 billion yen (92.5% Year-over-Year increase), and net income attributable to owners of parent was 16.072 billion yen (90.2% Year-over-Year increase).

For the third quarter of fiscal year ending February 2026, consolidated operating revenue was 605.927 billion yen (1.3% YoY increase), operating income was 4.812 billion yen (21.4% YoY decrease), and net income attributable to owners of parent was 3.095 billion yen (0.2% YoY decrease).

Fuji Corporation has transferred all shares of its equity-method affiliate Lady Pharmacy Co., Ltd., and expects to record extraordinary income of ¥8,189 million from sale of investment securities in the consolidated financial results for the fourth quarter of fiscal 2026 ending February, as well as extraordinary income of ¥17,447 million from sale of equity-method affiliate shares in its non-consolidated financial...

The full-year consolidated earnings forecast for the fiscal year ending February 2026 has been revised to operating revenue of 814,000 million yen (0.1% decrease from previous), operating income of 10,600 million yen (31.6% decrease), and net income attributable to owners of parent of 5,700 million yen (3.6% increase).